Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current


Minerva Neurosciences Receives Refusal To File Letter From FDA For New Drug Application For Roluperidone For Treatment Of Negative Symptoms In Schizophrenia

Author: Bill Haddad | October 17, 2022 07:33am

Posted In: NERV